Steroid-Responsive Meningitis Arteritis in Dogs: Welfare Management

Steroid-responsive meningitis arteritis (SRMA) is a common immune-mediated neurological condition in young dogs, causing severe pain and welfare impairment that responds well to early treatment.

Key Facts

SRMA typically affects young large breed dogs (6-18 months) — Beagles, Boxers, Bernese Mountain Dogs and Weimaraners are predisposed
Clinical signs include severe neck pain, arched posture, reluctance to move, pyrexia and profound depression
Diagnosis requires CSF analysis — neutrophilic pleocytosis is characteristic; CSF protein and IgA are elevated
Prognosis is excellent with appropriate long-term immunosuppressive treatment — relapse is the primary welfare risk

Welfare Considerations

SRMA imposes acute, severe welfare suffering — affected dogs are in extreme pain, unable to lower their heads, and show signs of profound neurological distress. Early diagnosis and treatment with high-dose corticosteroids produces dramatic welfare improvement within 24-48 hours. The welfare risk of inadequate or premature treatment cessation is relapse — which occurs in approximately 20-30% of cases. Long-term treatment protocols (minimum 6 months tapering steroids) substantially reduce relapse rates and thus long-term welfare burden.

What You Can Do

Seek immediate neurological assessment for any young dog presenting with severe neck pain and pyrexia
Begin high-dose prednisolone treatment promptly after diagnosis — welfare improvement within 24-48 hours is expected
Follow the full long-term tapering protocol — premature withdrawal is the most common cause of relapse
Monitor CSF at treatment milestones if possible — normalisation confirms adequate treatment response